<?xml version="1.0" encoding="UTF-8"?>
<p>Whilst viruses can cause tissue damage by direct cytopathic effects on the infected cells, morbidity and mortality in severe disease are typically attributable to the host inflammatory response, including in COVID‐19.
 <xref rid="rmv2163-bib-0057" ref-type="ref">
  <sup>57</sup>
 </xref> AZM and other macrolides have a number of immunomodulatory properties which have proven clinical efficacy in a broad range of respiratory diseases including asthma,
 <xref rid="rmv2163-bib-0029" ref-type="ref">
  <sup>29</sup>
 </xref> COPD,
 <xref rid="rmv2163-bib-0058" ref-type="ref">
  <sup>58</sup>
 </xref> post lung transplant obliterative bronchiolitis
 <xref rid="rmv2163-bib-0059" ref-type="ref">
  <sup>59</sup>
 </xref> and diffuse pan bronchiolitis (DPB).
 <xref rid="rmv2163-bib-0060" ref-type="ref">
  <sup>60</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0061" ref-type="ref">
  <sup>61</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0062" ref-type="ref">
  <sup>62</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0063" ref-type="ref">
  <sup>63</sup>
 </xref> In DPB, a dramatic increase in survival
 <xref rid="rmv2163-bib-0060" ref-type="ref">
  <sup>60</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0062" ref-type="ref">
  <sup>62</sup>
 </xref>, 
 <xref rid="rmv2163-bib-0063" ref-type="ref">
  <sup>63</sup>
 </xref> has been attributed to the ability of AZM to inhibit dysregulated IL‐1β, IL‐2, TNF and GM‐CSF.
 <xref rid="rmv2163-bib-0064" ref-type="ref">
  <sup>64</sup>
 </xref> Therefore, the anti‐inflammatory properties of AZM (summarised in Table 
 <xref rid="rmv2163-tbl-0002" ref-type="table">2</xref> and Figure 
 <xref rid="rmv2163-fig-0001" ref-type="fig">1</xref>) may be clinically important in the management of viral diseases.
</p>
